Loading stock data…
TLRY
$6.16-0.08 (-1.28%)
Market ClosedLast close May 1
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tilray Brands, Inc. in the Healthcare sector is trading at $6.16. The stock is currently near its 52-week low of $3.50, remaining 36.9% below its 200-day moving average. Technical signals show neutral RSI of 43 and bearish MACD signal, explaining why TLRY maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 43) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$6.16
Potential Upside
5%
Whystock Fair Value$6.47
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The compan...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$941.29M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.11
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-140.41%
Volume
Today's trading volume
4.08M
Recent News
Tilray (TLRY) CEO on Potential US Cannabis Reclassification
Tilray Brands, Inc. (NASDAQ:TLRY) is one of the 7 Best Hemp Stocks To Buy Now. On April 22, Bloomberg reported, citing an on-air discussion with CEO Irwin Simon, that Tilray Brands, Inc. (NASDAQ:TLRY) shares rose by around 10% after surging as much as 18% earlier, amid strong trading activity of more than 20 million shares. […]
Is Tilray a Textbook Example of a Value Trap?
Tilray doesn't fit squarely into the value trap or value stock categories.
Tilray just showed how fast a policy trade can cool off
Tilray Brands (TLRY) surged in premarket trading on fresh enthusiasm over marijuana rescheduling, then gave back much of the move as the session unfolded. The early excitement followed a U.S. government shift to reclassify certain marijuana products and a market rush into cannabis names. By later ...
Medical Marijuana Reclassified as Less Dangerous Drug. Pot Stocks Go Up in Smoke.
The Trump administration also announced the beginning of an expedited administrative hearing process to consider the rescheduling marijuana more broadly.
Pot firms reverse gains on narrow scope of US rescheduling
<body><p>STORY: Shares of cannabis firms reversed early gains on Thursday as investors took a closer look at the limited scope of the U.S. government's move to reclassify marijuana as a less-dangerous drug.</p><p>Cronos Group, Aurora Cannabis, Canopy Growth and Tilray Brands slumped between 7% and 15% in afternoon trading.</p><p>Shares of these companies had surged after Acting Attorney General Todd Blanche in a social media post said the Department of Justice was, quote, "immediately rescheduling FDA-approved marijuana and state-licensed marijuana from Schedule I to Schedule III." The department is also initiating an expedited hearing to consider the broader rescheduling of marijuana.</p><p>But industry insiders said the move stops short of a sweeping reclassification.</p><p>The CEO of FundCanna, which provides capital for cannabis companies, said the order applies specifically to FDA-approved cannabis drugs and products operating under state medical marijuana frameworks, rather than the broader market, creating uneven benefits across the sector.</p><p>A top executive at CB1 Capital Management added that the move was narrower than investors had hoped, rescheduling medical cannabis immediately while setting a June hearing on adult use...</p><p>with the market not understanding the, quote, "nuances involved, the opposition or the legal challenges." </p><p>Still, overall, the sector applauded the decision.</p><p>It would lift a major tax burden that is unique to the cannabis industry that had prevented some companies from claiming tax credits and writing off basic business expenses.</p><p>The reclassification could also ease access to funding as federal restrictions have long kept most banks and institutional investors on the sidelines, forcing cannabis producers to rely on costly loans or alternative lenders.</p></body>